A publication in Scientific Reports (2017), which supported the clinical rationale of efficacy and safety of low-dose doxycycline in diabetics, stated: “doxycycline not only ameliorated insulin resistance, fasting blood glucose, and insulin levels, and lipid profiles in the circulation and liver, but also improved islet morphology and increased glucose-stimulated insulin secretion.” Additional developments include the biphenolic chemically-modified curcumins, as HMT for managing oral diseases. This evidence concerns the gene INS and mouth disorder.